Calendario›OCUL›Artificial Tears
Artificial Tears
An Observational, Qualitative Study Assessing Eye Drop Administration
Ensayo de OCULAR THERAPEUTIX, INC en Ocular Injury (del registro, en inglés).
- Fase
- no aplica
- Estado
- Sin noticias del promotor
- Participantes
- 300
- Centros
- 1
- Fin del objetivo primario
- jul 2023
previstos
estimado por el promotor
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en abr 2022.
Qué mide
Proportion of patients who meet pre-specified "success" criteria for proper administration of eye drop onto ocular surface on first attempt session as evaluated by the ophthalmologist or optometrist grader (There will be a total of three eye drop administration attempts - Two attempts occur on the first visit (Day 0)) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is a prospective, observational, consecutive, qualitative, multicenter study. Based on the available published evidence that supports patient challenges with eyedrop administration, the purpose of this video-capture study is to evaluate a more real-world population of consenting patients, regardless of age, with or without visual impairment, at routine eyecare visits. To date, no studies have been performed evaluating a real-world population consisting of daily routine eyecare clinic patients with or without visual impairment. This study will help to determine the ability to achieve success with self-administration of eyedrops in the real world.
Más ensayos de OCUL
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| OTX-TKI | Fase 3 | En marcha, sin reclutar | abr 2026 (prevista, ya pasada: sin actualizar en el registro) |
| OTX-TKI | Fase 3 | En marcha, sin reclutar | ene 2027 (prevista) |
| HELIOS-3 | Fase 3 | Reclutando pacientes | mar 2027 (prevista) |
| OTX-TKI | Fase 3 | Reclutando pacientes | ago 2030 (prevista) |
| OTX-DED | Fase 2 | Completado | may 2024 (real) |
| OTX-TIC low dose Travoprost… | Fase 2 | Completado | ene 2024 (real) |
Todos los de OCUL, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT05307081), actualizada en sep 2022.